• 11/12/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of October 31st, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20241112_PR_shares_votingrights_october2024.pdf
  • 11/07/2024, Sophia Antipolis, France

    Median Technologies hosted insightful Key Opinion Leader (KOL) webinar on eyonis™ Lung Cancer Screening (LCS) REALITY data

    Two leading U.S. pulmonology experts Prof. Anil Vachani, and Prof. Javier Zulueta, provided their views on the data from REALITY, Median’s recently completed pivotal study of the eyonis™ LCS SaMD, and how the AI powered device may impact lung cancer diagnostics and treatment.
    Read more Download 20241107_PR_PostKOLwebinar_EN.pdf
  • 10/30/2024, Sophia Antipolis, France

    Median Technologies to host Key Opinion Leader (KOL) webinar on AI and lung cancer screening

    Median Technologies will host on November 7, 2024 at 1:30 pm CET / 7:30 am ET a KOL webinar to discuss REALITY, the recently completed study of the eyonis™ LCS SaMD for early diagnosis of lung cancer.
    Read more Download 20241030_PR_KOL_Webinar_EN-1.pdf
  • 10/24/2024, Sophia Antipolis, France

    Median Technologies Reports 2024 Q3 Operational and Financial Update and 2024 Half-Year Results

    Median Technologies announces today that its Board of Directors approved the consolidated IFRS financial statements for the first half of 2024 on October 23, 2024, and provides operational and financial updates from the third quarter of 2024.
    Read more Download 20241024_PR_H120234Q32024_final_EN.pdf
  • 10/07/2024,

    Disclosure of total number of voting rights and number of shares in the capital as of September 30th, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of September 30th, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20241007_PR_shares_votingrights_September2024.pdf
  • 09/11/2024, Sophia Antipolis, France

    Median Technologies to attend and present at the ESMO Congress 2024, being held in Barcelona, Spain, from Sept 13-17, 2024

    Median iCRO and eyonis™ teams will be present to welcome interested parties at Booth #525, Hall 3, from September 13-16 (exhibition dates). The Company will share the most recent advances for iCRO AI-powered clinical trial imaging services as well as latest developments for eyonis™ LCS SaMD. Median eyonis™ team will present a peer-reviewed poster presentation of the full positive results of the independent verification study for Median proprietary SaMD eyonis™ LCS.
    Read more Download 20240911_PR_ESMO2024_final_EN.pdf
  • 09/06/2024, Sophia Antipolis, France

    Disclosure of total number of voting rights and number of shares in the capital as of August 31st, 2024

    Disclosure of total number of voting rights and number of shares in the capital as of August 31st, 2024, pursuant to article L-223-8 II of the French “code de Commerce” and 223-16 of the AMF’s General Regulations.
    Read more Download 20240906_PR_shares_votingrights_August2024.pdf
  • 09/04/2024, Sophia Antipolis, France

    Median Technologies to share positive pivotal data for eyonis™ LCS diagnostic software as medical device at the IASLC 2024 World Conference on Lung Cancer (San Diego, CA, USA, from September 7-10, 2024)

    The Company will be sharing information on its proprietary AI/ML-powered SaMD, eyonis™ LCS, including recently announced data from the pivotal REALITY study, at Booth #2601 during the 2024 World Conference on Lung Cancer, being held in San Diego, CA, USA, from September 7-10, 2024. The WCLC, the premier world conference on lung cancer, is organized by the International Association for the Study of Lung Cancer, a global multidisciplinary association dedicated to eradication of all forms of lung cancers.
    Read more Download 20240904_PR_WCLC2024_EN.pdf
  • 09/02/2024, Sophia Antipolis, France

    Median Technologies to host two webcasts on September 5, 2024 – “eyonis™ LCS: New Horizons in Fighting Lung Cancer”

    Following the recent release of results of the eyonis™ LCS REALITY study, Fredrik Brag, CEO and Founder of Median Technologies, will offer further insights into the significance of eyonis™ LCS and discuss the next steps for Median’s novel Software as a Medical Device.
    Read more Download 20240902_PR_Webcast_EN.pdf
  • 08/29/2024, Sophia Antipolis, France

    Median Technologies announces pivotal REALITY study of its eyonis™ LCS lung cancer diagnostic met all primary and secondary endpoints

    Median Technologies announces today that eyonis™ LCS, its proprietary AI/ML-powered Software as Medical Device for lung cancer screening, met the primary and all secondary endpoints in REALITY, the first of two pivotal studies required for marketing authorizations in U.S. and Europe.
    Read more Download 20240829_PR_REALITY_EN_final.pdf
    • 1 … 39